Drug intelligence / Profile preview

Cromagen

Development stage
Phase 4
Lead developer
Valdecasas
Modality
Small Molecules
Administration
Oral
01

Overview

Cromagen (also known as Cromagen A.F.) is an approved fixed-dose combination of three essential B-complex vitamins: folic acid (vitamin B9), pyridoxine (vitamin B6), and cyanocobalamin (vitamin B12). Developed by Valdecasas, it is marketed in Mexico for the correction of vitamin deficiencies and as an auxiliary treatment to lower homocysteine levels in patients with nutritional hyperhomocysteinemia. Folic acid, pyridoxine, and cyanocobalamin play critical roles in cellular metabolism, DNA synthesis, and red blood cell production. Together, they act synergistically to facilitate the conversion of homocysteine to methionine, thereby reducing cardiovascular and neurological risks associated with elevated homocysteine levels.

Brand names
CromagenCromagen A.F.
Other names
cianobalamina + ácido fólico + piridoxinacyanocobalamin + folic acid + pyridoxinecyanocobalamin + folic acid + pyridoxine hydrochloridefolic acid + pyridoxine + cyanocobalaminpiridoxina + cianocobalamina + ácido fólico
02

Targets

DHFR (Dihydrofolate reductase)MTR (Methionine synthase)MMUT (Methylmalonyl-coenzyme A mutase)PDXK (Pyridoxal kinase)

Beyond the preview

Go deeper on Cromagen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cromagen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call